Search

Author/Creator Dummer, Reinhard

1. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016)

Authors:
Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 4:Issue 1(2016)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016)

Authors:
Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 4:Issue 1(2016)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016)

Authors:
Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia Masvidal; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine A.; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy A.;...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 4(2016)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma. (9th November 2020)

Authors:
Long, Georgina; Dummer, Reinhard; Johnson, Douglas; Michielin, Olivier; Martin-Algarra, Salvador; Treichel, Sheryl; Chan, Edward; Diede, Scott; Ribas, Antoni
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A261
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma. (9th November 2020)

Authors:
Long, Georgina; Dummer, Reinhard; Johnson, Douglas; Michielin, Olivier; Martin-Algarra, Salvador; Treichel, Sheryl; Chan, Edward; Diede, Scott; Ribas, Antoni
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A454
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. 432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma. (9th November 2020)

Authors:
Dummer, Reinhard; Gyorki, David; Hyngstrom, John; Berger, Adam; Conry, Robert; Demidov, Lev; Chan, Edward; Radcliffe, Hoi-Shen; Faries, Mark; Ross, Merrick
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A263
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. 432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma. (9th November 2020)

Authors:
Dummer, Reinhard; Gyorki, David; Hyngstrom, John; Berger, Adam; Conry, Robert; Demidov, Lev; Chan, Edward; Radcliffe, Hoi-Shen; Faries, Mark; Ross, Merrick
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A458
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. (18th July 2017)

Authors:
Izar, Benjamin; Sharfman, William; Hodi, F. Stephen; Lawrence, Donald; Flaherty, Keith T.; Amaravadi, Ravi; Kim, Kevin B.; Puzanov, Igor; Sosman, Jeffrey; Dummer, Reinhard; Goldinger, Simone M.; Lam, Lyhping; Kakar, Shefali; Tang, Zhongwen; Krieter, Oliver; McDermott, David F.; Atkins, Michael B.
Journal:
Cancer medicine
Issue:
Volume 6:Number 8(2017:Aug.)
Page Start:
1904
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. A new live‐cell biobank workflow efficiently recovers heterogeneous melanoma cells from native biopsies. Issue 5 (May 2015)

Authors:
Raaijmakers, Marieke I. G.; Widmer, Daniel S.; Maudrich, Melanie; Koch, Tabea; Langer, Alice; Flace, Anna; Schnyder, Claudia; Dummer, Reinhard; Levesque, Mitchell P.
Journal:
Experimental dermatology
Issue:
Volume 24:Issue 5(2015:May)
Page Start:
377
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. A paracrine activin A–mDia2 axis promotes squamous carcinogenesis via fibroblast reprogramming. Issue 4 (9th March 2020)

Authors:
Cangkrama, Michael; Wietecha, Mateusz; Mathis, Nicolas; Okumura, Rin; Ferrarese, Luca; Al‐Nuaimi, Dunja; Antsiferova, Maria; Dummer, Reinhard; Innocenti, Metello; Werner, Sabine
Journal:
EMBO molecular medicine
Issue:
Volume 12:Issue 4(2020)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗